Abstract:Objective: We investigated the effect of intramuscular injections of long-acting bromocriptine in patients with macroadenomas. Study design and patients: Thirty patients with PRL-secreting pituitary macroadenomas were treated with repeated 4-weekly intramuscular injections of 50 or 100 mg of a long-acting, repeatable bromocriptine formulation for six to 37 injections, amounting to a total of 473 injections. Twenty patients received parenteral bromocriptine as primary therapy, ten had persisting hyperprolactinemia after previous therapies including pituitary surgery (n = 7), oral bromocriptine (7), and pituitary irradiation (2). Measurements: A PRL day profile was obtained and the patients' clinical status and history were documented, at intervals. Detailed clinical, laboratory, and radiological (pituitary nuclear magnetic resonance or computed tomography scan) evaluations were performed at baseline, after 1 injection and every 6th injection thereafter. Results: In all patients PRL was suppressed from a mean +/- SEM pretreatment level of 32,620 +/- 8680 to 4480 +/- 1140 mU/I on the third day after the first injection. In 12 patients PRL levels normalized (< 400 mU/I) with the first to fourth injection, in three additional patients PRL levels normalized after 8-15 months. In 19 patients PRL was suppressed to less than 1000 mU/l. In three patients PRL did not decrease to less than 50% of pretreatment; in two of them on oral bromocriptine prior to this study there had been a comparable low efficacy. Of 28 patients with macroadenomas (median height 22 mm) tumour shrinkage was evident in 15 by nuclear magnetic resonance or computed tomography scan 28 days after the first injection, and in three additional patients after 6 months. There was further regression in seven cases after 12, 18 or 24 injections. Adenoma size (mean +/- SEM) decreased to 66 +/- 7% of the pretreatment value. The 40 adverse events noted in 20 of 30 patients during 24 hours after the first injection were similar to known side-effects of oral bromocriptine, nausea and postural hypotension being the most frequent. With repeated injections, on average 0.6 adverse events were noted per injection (mostly mild asthenia). There were no local adverse reactions at the injection site. Conclusion: We conclude that long-acting repeatable bromocriptine in patients with macroprolactinomas offers a safe and efficacious primary treatment that ensures compliance and gives long-term control. Adverse reactions are comparable to oral bromocriptine but subside with repeated injections.

Efficacy of Moderate Dose Bromocriptine by One-off Oral Administration in Patients with Non-Acute Prolactin Type Pituitary Adenoma

[Effects of bromocriptine on the treatment of prolactinomas in male patients and its influences on their sexual function]

Curative Effect and Mechanism of Bromocriptine on Pituitary Prolactinoma

Analysis of the Correlation Between Bromocriptine and Consistence and Apoplexy of Prolactinomas

The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia

Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist

Meta-analysis of Effectiveness and Safety of Bromocriptine by Vaginal Delivery for Hyperprolactinemia in Chinese Female Patients

Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia

Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years

Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety

Long-term follow-up of 246 hyperprolactinemic patients

Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia

Surgery versus bromocriptine for female patients with prolactinoma in China:A Meta-a-nalysis

[Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction]

Cabergoline for the Treatment of Bromocriptine-Resistant Invasive Giant Prolactinomas

Cabergoline Versus Bromocriptine for the Treatment of Giant Prolactinomas: A Quantitative and Systematic Review

A Comparative Study of Surgery and Drug Therapy for Adult Prolactinomas

Dopamine receptor agonists for treating prolactinomas

Inhibition of Skp2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells

Sex-related Changes in Tumor Consistency in Prolactinoma Patients after Bromocriptine Pretreatment ⁎

Sexual Functioning in Hyperprolactinemic Patients Treated With Cabergoline or Bromocriptine